GIST adjuvant therapy-some answers and more questions

被引：0
|
作者：
Eisenberg, Burton [1 ]
机构：
[1] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Lebanon, NH 03756 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 08期
关键词：
GASTROINTESTINAL STROMAL TUMORS; IMATINIB MESYLATE; DOSE IMATINIB; TRIAL; KIT;
D O I：
10.1038/nrclinonc.2009.104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Imatinib is known to be effective in the first-line treatment of metastatic gastrointestinal stromal tumors. a randomized, placebo-controlled trial has now shown that imatinib is safe and improves recurrence-free survival when used as adjuvant therapy after surgical resection of a primary gastrointestinal stromal tumor.
引用
收藏
页码：441 / 442
页数：3
相关论文
共 40 条
  • [31] Adjuvant Therapy for Biliary Tract Cancers: New Evidence to Resolve Old Questions
    Cloyd, Jordan M.
    Pawlik, Timothy M.
    JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (12) : 722 - 724
  • [32] The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy
    Guerin, Annie
    Sasane, Medha
    Gauthier, Genevieve
    Keir, Christopher H.
    Zhdavana, Maryia
    Wu, Eric Q.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 241 - 248
  • [33] The Efficacy of Sublingual Lorazepam for Prolonged Convulsions Beyond Sub-Saharan Africa: Raising More Questions Than Answers
    Ng, Yu-Tze
    JOURNAL OF CHILD NEUROLOGY, 2014, 29 (11) : 1572 - 1573
  • [34] Patient with high-risk GIST not associated with c-KIT mutations: Same benefit from adjuvant therapy?
    Ortega Izquierdo, Ma Eugenia
    Taberner Bonastre, Ma Teresa
    ANTI-CANCER DRUGS, 2012, 23 : S7 - S9
  • [35] The impact of contour maps on estimating the risk of gastrointestinal stromal tumor recurrence: indications for adjuvant therapy: an analysis of the Kinki GIST registry
    Ryugo Teranishi
    Tsuyoshi Takahashi
    Shinsuke Sato
    Katsunobu Sakurai
    Kentaro Kishi
    Hisahiro Hosogi
    Takuya Nakai
    Yukinori Kurokawa
    Junya Fujita
    Toshirou Nishida
    Seiichi Hirota
    Toshimasa Tsujinaka
    Gastric Cancer, 2024, 27 : 355 - 365
  • [36] The impact of contour maps on estimating the risk of gastrointestinal stromal tumor recurrence: indications for adjuvant therapy: an analysis of the Kinki GIST registry
    Teranishi, Ryugo
    Takahashi, Tsuyoshi
    Sato, Shinsuke
    Sakurai, Katsunobu
    Kishi, Kentaro
    Hosogi, Hisahiro
    Nakai, Takuya
    Kurokawa, Yukinori
    Fujita, Junya
    Nishida, Toshirou
    Hirota, Seiichi
    Tsujinaka, Toshimasa
    GASTRIC CANCER, 2024, 27 (02) : 355 - 365
  • [37] Comparison of the long-term risk of recurrence and other clinical outcomes in gist patients receiving imatinib as adjuvant therapy-a retrospective chart extract-based approach
    Conley A.P.
    Guérin A.
    Sasane M.
    Gauthier G.
    Schwiep F.
    Hunt Keir C.
    Wu E.Q.
    Journal of Gastrointestinal Cancer, 2013, 44 (2) : 190 - 198
  • [38] Taking the "Goal-Directed" Out of Early Goal-Directed Therapy for Sepsis? Answers to the March 2015 Journal Club Questions
    Crager, Sara E.
    ANNALS OF EMERGENCY MEDICINE, 2015, 66 (02) : 201 - 211
  • [39] A Role for Adjuvant RFA in Managing Hepatic Metastases from Gastrointestinal Stromal Tumors (GIST) After Treatment with Targeted Systemic Therapy Using Kinase Inhibitors
    Antoine Hakimé
    Axel Le Cesne
    Frederic Deschamps
    Geoffroy Farouil
    Sana Boudabous
    Anne Aupérin
    Julien Domont
    Thierry Debaere
    CardioVascular and Interventional Radiology, 2014, 37 : 132 - 139
  • [40] Selection Bias Is Not a Good Reason for Advising More Than 5 Years of Adjuvant Hormonal Therapy for All Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy
    Collette, Laurence
    Studer, Urs E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : E201 - E202
1234